Form 4 for IRD Opus Genetics, Inc.
Accepted 2021-07-02 00:00:00 ET · period of report 2021-07-01 · accession 0001140361-21-023334 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-07-02 | 2021-07-01 | IRD | Rodgers Richard J | Dir | A - Grant | — | +2,840 | 29.1K | +11% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-01 | A | A | 2,840 | — | 29,061 | D | — | — | (F1) The Reporting Person was granted common stock in lieu of cash for Q2 2021 Board services. The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $5.28 per share, the closing price of the Company's stock on June 30, 2021. |